Group 1 - The company is in the research phase for injectable isavuconazole, which is aimed at treating invasive fungal infections such as invasive aspergillosis and invasive mucormycosis [2] - The injectable isavuconazole is classified as a Category 4 chemical drug for registration purposes [2] - The company expressed gratitude for investor interest in its projects [2]